The University of Chicago Header Logo

Connection

Mark J. Ratain to Protein-Tyrosine Kinases

This is a "connection" page, showing publications Mark J. Ratain has written about Protein-Tyrosine Kinases.
Connection Strength

1.214
  1. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013 Mar; 93(3):242-4.
    View in: PubMed
    Score: 0.395
  2. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med. 2006 Nov 07; 145(9):702-3.
    View in: PubMed
    Score: 0.259
  3. EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
    View in: PubMed
    Score: 0.228
  4. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol. 2011 Jun; 71(6):917-20.
    View in: PubMed
    Score: 0.089
  5. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.089
  6. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
    Score: 0.085
  7. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6788-95.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.